Gina Novo Nordisk - Search News

Novo Nordisk Expands AI Partnership With Valo Health

Novo Nordisk and Valo expand cardiometabolic drug partnership

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets. The collaboration,

Hosted on MSN · 1d

Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).

GEN · 1d

Novo Nordisk, Valo Health Ink Expanded Up-to-$4.6B AI Collaboration

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial intelligence (AI) partnership aimed at discovering and developing up to 20 treatments for obesity,

Seeking Alpha on MSN · 1d

Novo Nordisk, Valo Health expand drug discovery deal

Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to expand their existing collaboration to discover and develop new treatments targeting cardiometabolic diseases.

Novo Nordisk upgraded to Buy from Neutral at UBS

Investopedia on MSN · 1d

Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'

Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock to "buy" from "neutral," calling the recent sell-off of the stock "overdone.

Business Insider · 1d

Novo Nordisk upgraded to Buy from Neutral at UBS, as CagriSema selloff overdone

UBS analyst upgraded Novo Nordisk (NVO) to Buy from Neutral with a price target of DKK 750, down from DKK 1,100. Novo Nordisk is “well placed”

Fintel on MSN · 23h

UBS Upgrades Novo Nordisk A (NVO)

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst Price Forecast Suggests 61.15% Upside As of December 23, 2024, the average one-year price target for Novo Nordisk A is $137.

Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

1don MSN

Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Becker's Hospital Review1d

Novo Nordisk joins Eli Lilly in legal challenge over GLP-1 compounding

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

Business Wire1mon

Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development

Concurrent with its investment, Miriam Frieden, Novo Nordisk’s Corporate Vice President of Early Innovation, Outreach and Alliances will join Eikonizo’s Board of Directors as a non-voting ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results